Compare Amphastar Pharmaceuticals Inc (AMPH) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs CarMax, Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while CarMax, Inc trades at $58.03 (market cap $8.34B). The key difference: CarMax, Inc is far larger — about 9.7× Amphastar Pharmaceuticals Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | KMX | |
|---|---|---|
Market Cap | $863.95M | $8.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $62.17 |
52-Week Low | $16.87 | $30.88 |
Enterprise Value | $1.26B | $26.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
CarMax (KMX) trades at $58.18, up 0.21% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance, beating expectations in Q3 2025 and Q1 2026 but missing in Q2 2025. Revenue has declined from $31.9B in 2022 to $26.35B in 2025, while net income margin improved slightly to 1.89%. Recent news includes partnerships to enhance customer experience and ongoing legal investigations into fiduciary duties.
Outlook is cautious with a consensus price target of $53.09 below the current price, indicating potential downside. Opportunities lie in operational improvements and AI integrations, but risks include high debt, competitive pressures, and legal scrutiny. Analyst sentiment is neutral with 68.58% hold ratings, suggesting wait-and-see approach amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
